Additionally, over the last 4–5 years there has been an increase in the number of studies investigating LOXL2 expression in patient samples from a significant number of highly aggressive cancers of different origins: pancreatic adenocarcinoma [39,40,41], cervical carcinoma [42,43], osteosarcoma [44], oesophageal cancer [16], hepatocellular carcinoma [45], renal clear cell carcinoma [46], oral squamous cell carcinoma [47], and breast cancer [48,49,50] (summarised in Dataset S1). This evidence concerns the gene LOXL2 and pancreatic adenocarcinoma.